The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma.

ABSTRACT:

Purpose of review

Multiple myeloma (MM) is a hematologic malignancy of plasma cells that remains incurable with currently available therapies including proteosome inhibitors, immunomodulators, monoclonal antibodies, corticosteroids, and alkylators, in addition to autologous stem cell transplantation in patients who are eligible. Novel therapeutics are therefore required to improve patient outcomes. The goal of this paper is to review the role of three new agents in the MM treatment landscape: belantamab mafodotin, selinexor, and melflufen.

Recent findings

All three agents have demonstrated clinical activity in patients with MM. Belamaf is the first FDA-approved anti-BCMA targeted agent, showing single-agent response rates of 60% and higher response rates of 48-100% in combin

SUBMITTER: McCurdy A 

PROVIDER: S-EPMC9684923 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature